Logo image of IVA

INVENTIVA SA - ADR (IVA) Stock Fundamental Analysis

NASDAQ:IVA - Nasdaq - US46124U1079 - ADR - Currency: USD

2.84  +0.1 (+3.65%)

Fundamental Rating

2

IVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. IVA may be in some trouble as it scores bad on both profitability and health. IVA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVA has reported negative net income.
IVA had a negative operating cash flow in the past year.
In the past 5 years IVA always reported negative net income.
In the past 5 years IVA always reported negative operating cash flow.
IVA Yearly Net Income VS EBIT VS OCF VS FCFIVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

IVA has a Return On Assets of -264.26%. This is amonst the worse of the industry: IVA underperforms 93.43% of its industry peers.
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROIC N/A
ROA(3y)-82.07%
ROA(5y)-64.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVA Yearly ROA, ROE, ROICIVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVA Yearly Profit, Operating, Gross MarginsIVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IVA has more shares outstanding than it did 1 year ago.
IVA has more shares outstanding than it did 5 years ago.
IVA has a worse debt/assets ratio than last year.
IVA Yearly Shares OutstandingIVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
IVA Yearly Total Debt VS Total AssetsIVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -17.85, we must say that IVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IVA (-17.85) is worse than 85.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.85
ROIC/WACCN/A
WACC7.49%
IVA Yearly LT Debt VS Equity VS FCFIVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

IVA has a Current Ratio of 0.59. This is a bad value and indicates that IVA is not financially healthy enough and could expect problems in meeting its short term obligations.
IVA's Current ratio of 0.59 is on the low side compared to the rest of the industry. IVA is outperformed by 92.54% of its industry peers.
A Quick Ratio of 0.59 indicates that IVA may have some problems paying its short term obligations.
IVA's Quick ratio of 0.59 is on the low side compared to the rest of the industry. IVA is outperformed by 92.36% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59
IVA Yearly Current Assets VS Current LiabilitesIVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.74% over the past year.
IVA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.92%.
IVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.46% yearly.
EPS 1Y (TTM)20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y260.83%
Revenue growth 5Y40.46%
Sales Q2Q%-97.84%

3.2 Future

The Earnings Per Share is expected to grow by 10.06% on average over the next years. This is quite good.
The Revenue is expected to grow by 50.72% on average over the next years. This is a very strong growth
EPS Next Y-2.11%
EPS Next 2Y10.44%
EPS Next 3Y7.97%
EPS Next 5Y10.06%
Revenue Next Year-51.09%
Revenue Next 2Y20.61%
Revenue Next 3Y30.53%
Revenue Next 5Y50.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IVA Yearly Revenue VS EstimatesIVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
IVA Yearly EPS VS EstimatesIVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVA. In the last year negative earnings were reported.
Also next year IVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVA Price Earnings VS Forward Price EarningsIVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVA Per share dataIVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.44%
EPS Next 3Y7.97%

More info and screens

0

5. Dividend

5.1 Amount

IVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA - ADR

NASDAQ:IVA (2/21/2025, 8:00:02 PM)

2.84

+0.1 (+3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)07-29 2025-07-29
Inst Owners44.45%
Inst Owner Change-69.85%
Ins Owners9.93%
Ins Owner ChangeN/A
Market Cap148.71M
Analysts88
Price Target9.63 (239.08%)
Short Float %0.86%
Short Ratio43.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.09%
PT rev (3m)-19.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)6.56%
EPS NY rev (3m)6.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)16.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.7
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0.31
BVpS-1.58
TBVpS-1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.07%
ROA(5y)-64.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.93%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -17.85
F-Score3
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.81%
Cap/Sales(5y)20.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
EPS Next Y-2.11%
EPS Next 2Y10.44%
EPS Next 3Y7.97%
EPS Next 5Y10.06%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y260.83%
Revenue growth 5Y40.46%
Sales Q2Q%-97.84%
Revenue Next Year-51.09%
Revenue Next 2Y20.61%
Revenue Next 3Y30.53%
Revenue Next 5Y50.72%
EBIT growth 1Y10.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.44%
EBIT Next 3Y7.99%
EBIT Next 5Y13.49%
FCF growth 1Y-55.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.73%
OCF growth 3YN/A
OCF growth 5YN/A